Role of Iron Chelation Therapy in Thalassemia Major.
نویسنده
چکیده
iron chelating therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Although desferrioxamine (DFO) has been available for treating transfusional iron overload from the early 1960s, the era of modern and effective iron chelating therapy started only 20 years ago with the introduction of subcutaneous DFO infusions by portable pumps. Today, long-term DFO therapy is an integral part of the management of thalassemia and other transfusion-dependent anemias, with a major impact on well-being and survival[1,2].
منابع مشابه
Triple Drug Iron Chelation Therapy in Thalassemia Major; A Case Report
Regular packed cell transfusion in patients with thalassemia major leads to iron overload. Chelation therapy is one of the important aspects of thalassemia care as iron overload causes significant cardiac, hepatic, and endocrine dysfunction. We report a case of thalassemia major with severe iron overload causing cardiac and liver dysfunction who benefitted from triple drug chelation therapy. Tr...
متن کاملRegular Reminding of the Potential Serious Complications of Poor Adherence to Treatment: A Strategy for Improving Treatment Adherence in Beta-Thalassemia Major Patients
Globally, β-Thalassemia Major (β-TM) is the most commonly inherited hemolytic anemia, with a high incidence rate in Southeast Asia, the Middle East and Mediterranean countries. Patients with β-TM require lifelong adherence to their distressing treatment regimens, including regular blood transfusions and daily chelation therapy.
متن کاملبررسی عوارض قلبی و مرگ و میر ناشی از آن در بیماران بتاتالاسمی ماژور در 10 سال گذشته در بیمارستان حضرت علی‌اصغر(ع)
Cardiac symptoms and premature death from cardiac causes are still major problem with beta thalassemia despite chelation therapy. Heart complications are the leading causes of mortality in the absence of effective iron chelation therapy. Many patients develop evidence of iron-induced myocardial damage with cardiac failure, cardiac arrhythmia, sudden death or death from progressive conge...
متن کاملA Glance at the Cost of Chelation Therapy with Desferal and Exjade in Iran
Background: Thalassemia is a series of hemoglobinopathies in which the production of perfect hemoglobin is completely or partially suppressed. Using injectable iron chelators have been dominating treatment for the iron overload caused by recurrent blood transfusions in thalassemic patients, however, a new oral iron chelating drug (Exjade) have been recently introduced and might be cost effec...
متن کاملEffect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial
Background: Patients with transfusional iron overload have depended on iron chelation therapy and improving chelation regimens have been of the highest priority. The aim of this study was to compare effect of combined versus monotherapy with Deferoxamine (DFO) and Deferiprone (DFP) in iron overloaded beta thalassemia (BT) major patients Materials and Methods We studied 36 BT major patients (mea...
متن کاملBrazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently there are three iron chelating agents available for continuous use in patients with thalassemia o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Turkish journal of haematology : official journal of Turkish Society of Haematology
دوره 19 2 شماره
صفحات -
تاریخ انتشار 2002